hmmm....EBITDA in FY20 & FY21 was ~12m off revenues of 100-105m
FY2022 forecast revenues of 115m (so a ~9% inprovement) but resulting in a reduction in EBITDA ("low single-digit").
Their June strategy presentation indicated (at least for FY21) that EBITDA would be ~10% of revenues and long term (FY24) would improve to 15-20%, but this guidance seems to actually show EBITDA margins reducing.....more spend on R&D and S&M in the short term??
GTK Price at posting:
$1.55 Sentiment: None Disclosure: Not Held
